Accès ouvert déclaré
2016
article
A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
Andrew McGarry, Michael McDermott, Karl Kieburtz, Elisabeth A. de Blieck, F Béal, Karen Marder, Christopher A. Ross, Ira Shoulson, Peter R. Gilbert, William Mallonee, Mark Guttman, Joanne Wojcieszek, Rajeev Kumar, Mark S. LeDoux, Mary Jenkins, H. Diana Rosas, Martha Nance, Kevin Biglan, Peter G. Como, Richard Dubinsky, Kathleen M. Shannon, Padraig O’Suilleabhain, Kelvin L. Chou, Francis O. Walker, W. R. Wayne Martin, Vicki Wheelock, Elizabeth McCusker, Joseph Jankovic, Carlos Singer, Juan Sanchez‐Ramos, B.L. Scott, Oksana Suchowersky, Stewart A. Factor, Donald S. Higgins, Eric Molho, Fredy J. Revilla, John N. Caviness, Joseph H. Friedman, Joel S. Perlmutter, Andrew Feigin, Karen E. Anderson, Ramon L. Rodriguez, Nikolaus R. McFarland, Russell L. Margolis, Eric S. Farbman, Lynn A. Raymond, Valerie Suski, Sandra K. Kostyk, Amy Colcher, Lauren Seeberger, Eric A. Epping, Sherali Esmail, Nancy Díaz, Wai Lun Alan Fung, Alan Diamond, Samuel Frank, Philip Hanna, Neal Hermanowicz, Leon Dure, Merit Cudkowicz, John Adams, Mandar Jog, Christopher Hyson, Sarah Furtado, Andrew P. Duker, Melissa J. Armstrong, Christian Lachner, Hubert Fernandez, Michael S. Okun, David Shprecher, Michael S. Cartwright, Clement T. Loy, Joohi Jiminez-Shahed, B. Robottom, Gregory Suter, Theresa HM Moore, Jane Forsyth, Andrea Hurt, Joann Belden, Katie Price, Diane Erickson, Breanna Nickels, Misty M. Thompson, Linda Cole, Julie Megens, Emilija Makaji, Sara-Lynn Masse, Keith Malarick, Louisa Mook, Susan Maya, Alex Bender, Jessica Meyer, Puja Turakhia, Katherine Harwood, Kathryn Duderstadt, S. Lenarz, Judy Hamerlinck, Patricia Edern, Charlyne Hickey, Ashley Owens, Clare Gibbons, Carolyn Steele Gray, Jean A. Jaglin, Kimberly Janko, Holly Lawrence, B. Estes, Brigid Hayward, Allison E. Johnson, Amit Gode, Giselle Huet, Beverly Romero-Kersh, K. Wernette, Elizabeth Sullivan, Jamie Guyot, Julie Konkle, Christine J. O’Neill, Pamela King, Amanda Martin, John Bautista, Nicole Mans, Jane Griffith, Erica Surles, Sharon Halton, Alicia Palao, Nathalie Padron, Kolleen Elliott, Lynn Elizabeth Oelke, London Butterfield, Peggy Perry-Trice, Sarah Wyne, Carol Pantella, Lorelei Tainsh, Elaine Sperin, Sharon Evans, Maureen Gartner, Amy Duffy, Pamela Kristof, Lisa Niles, Steven Rainone, Angie Wernle, Ronda Clouse, Michelle Cines, Kelly Dustin, Maura Deeley, Stacy Merritt, Heather Ferreri, Alison McMurray, Alanna Sheinberg, Marsha Hughes-Gay, Kori A. LaDonna, Erin Chung, Jennifer Y. Lee, Rachel Goldstein, Lindsay Esposito, Nicholas Scoglio, Matthew J. Grana, Carol Zimmerman, Lucia M. Blasucci, William Thayer, Jennifer Hawkins, J. Koch, Victoria Hunt, Jessica Bargoil, Ingrid U. Scott, Terry Tempkin, Linda Stewart, Emily Hayes, Donna Galea, Beatriz Belmar, Kylie Richardson, Christine Hunter, Ernesto Jiménez, Mónica Quesada, Wendy Levy, Anita Blenke, Lisa Gauger, Joanna Stoner, Mary Lou Klimek, Barbara Sommerfeld, Mary Eglow, Katy Regan, Erin Neefus, Marie Malikowski, Teri Radam, Marci Zomok, Margaret C. Lannon, Rhonda Agramonte, Johanna M Hartlein, Constance Nickerson, Samantha M. Gibson, Camille Swartz, Anne Smith-Bova, Randi Jones, Catherine L. Wielinski, Shanthi Graham, David G. Gunn, Jillian McMillan
138Citations signalées, ce qui n’est pas une note de qualité
3Institutions déclarées
1Pays d’affiliation déclarés
Rattachement africain : us.
Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
OBJECTIVE: To test the hypothesis that chronic treatment of early-stage Huntington disease (HD) with high-dose coenzyme Q10 (CoQ) will slow the progressive functional decline of HD. METHODS: We performed a multicenter randomized, double-blind, placebo-controlled trial. Patients with early-stage HD (n = 609) were enrolled at 48 sites in the United States, Canada, and Australia from 2008 to 2012. Patients were randomized to receive either CoQ 2,400 mg/d or matching placebo, then followed for 60 months. The primary outcome variable was the change from baseline to month 60 in Total Functional Capacity score (for patients who survived) combined with time to death (for patients who died) analyzed using a joint-rank analysis approach. RESULTS: An interim analysis for futility revealed a conditional power of <5% for the primary analysis, prompting premature conclusion in July 2014. No statistically significant differences were seen between treatment groups for the primary or secondary outcome measures. CoQ was generally safe and well-tolerated throughout the study. CONCLUSIONS: These data do not justify use of CoQ as a treatment to slow functional decline in HD. CLINICALTRIALSGOV IDENTIFIER: NCT00608881. CLASSIFICATION OF EVIDENCE: This article provides Class I evidence that CoQ does not slow the progressive functional decline of patients with HD.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease
- Date Crossref
- 10/01/2017
- Éditeur
- Ovid Technologies (Wolters Kluwer Health)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Les institutions déclarées
Une affiliation ne permet pas de déduire la nationalité d’un auteur.
Les sujets associés
Coenzyme Q10 studies and effectsGenetic Neurodegenerative DiseasesDNA Repair Mechanisms